Results 31 to 40 of about 11,568,194 (143)

Cerebral Amyloid Angiopathy: Emerging Concepts [PDF]

Journal of Stroke, 2015
Cerebral amyloid angiopathy (CAA) involves cerebrovascular amyloid deposition and is classified into several types according to the amyloid protein involved.
Masahito Yamada
doaj   +1 more source

Amyloid and tau PET in cerebral amyloid angiopathy-related inflammation two case reports and literature review

Frontiers in Neurology, 2023
BackgroundCerebral amyloid angiopathy-related inflammation (CAA-ri) is a clinical syndrome characterized by MRI findings of amyloid-related imaging abnormalities-edema (ARIA-E) suggestive of autoimmune and inflammatory reaction and hemorrhagic evidence ...
Jhih-Yong Yang, Yung-Tsai Chu, Hsin-Hsi Tsai, Hsin-Hsi Tsai, Jiann-Shing Jeng   +4 more
doaj   +1 more source

Case report and risk factor analysis of amyloid-related imaging abnormalities induced by lecanemab in Alzheimer's disease [PDF]

Zhenduanxue lilun yu shijian
Amyloid-related imaging abnormalities (ARIA) represent a significant safety concern that requires attention during the treatment of Alzheimer's disease (AD) with lecanemab, and their occurrence is associated with multiple factors.
XU Chenhaoyi, LIU Jingwen, FANG Min
doaj   +1 more source

Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease

Frontiers in Neurology, 2022
Second-generation anti-amyloid monoclonal antibodies are emerging as a viable therapeutic option for individuals with prodromal and mild dementia due to Alzheimer's disease (AD).
Charles G. Withington, R. Scott Turner
doaj   +1 more source

Multiple events lead to dendritic spine loss in triple transgenic Alzheimer's disease mice [PDF]

, 2010
The pathology of Alzheimer's disease (AD) is characterized by the accumulation of amyloid-β (Aβ) peptide, hyperphosphorylated tau protein, neuronal death, and synaptic loss.
Fuhrmann Martin, Kretzschmar Hans, Ochs, Simon M., Herms Jochen, Simon M Ochs, Burgold Steffen, Jochen Herms, Frank M LaFerla, Burgold, Steffen, Herms, Jochen, Hans Kretzschmar, Gerda Mitteregger, Fuhrmann, Martin, Kretzschmar, Hans, Ochs Simon M., Frank M. Laferla, LaFerla Frank M., Hoffmann, Nadine, LaFerla, Frank M., Bittner, Tobias, Bittner Tobias, Mitteregger, Gerda, Nadine Hoffmann, Simon M. Ochs, Martin Fuhrmann, Tobias Bittner, Hoffmann Nadine, Steffen Burgold, Mitteregger Gerda   +28 more
core   +2 more sources

Evaluating clinical meaningfulness of anti-β-amyloid therapies amidst amyloid-related imaging abnormalities concern in Alzheimer's disease. [PDF]

Brain Commun
Alzheimer’s disease is the most prevalent form of dementia in the elderly, which is clinically characterized by a gradual and progressive deterioration of cognitive functions.
Aljuhani M, Ashraf A, Edison P.
europepmc   +2 more sources

Amyloid tracers detect multple binding sites in Alzheimer´s disease brain tissue. [PDF]

, 2013
Imaging fibrillar amyloid-β deposition in the human brain in vivo by positron emission tomography has improved our understanding of the time course of amyloid-β pathology in Alzheimer’s disease. The most widely used amyloid-β imaging tracer so far is 11C-
Nordberg, A,, Ni, Ruiqing, Marutle, Amelia, Gillberg, P-G, Marutle, A,, Bergfors, A, Nordberg, Agneta, Gillberg, Per-Göran, Bergfors, Assar, Ni, R,   +9 more
core   +1 more source

Diffusion imaging shows abnormalities after blunt head trauma when conventional magnetic resonance imaging is normal [PDF]

, 2001
The investigation and management of patients after head injury must include the accurate and complete identification of cerebral damage. Using diffusion tensor imaging, abnormalities of diffusion in patients with head injuries and unremarkable MRI have ...
F J Rugg-Gunn, DUNCAN, JS, Duncan, J.S., SYMMS, MR, RUGG-GUNN, FJ, Barker, Gareth; id_orcid, GREENWOOD, R, Barker, G.J., Greenwood, R., Symms, M.J., Rugg-Gunn, F.J.   +10 more
core   +1 more source

Vessels Sing Their ARIAs: The Role of Vascular Amyloid in the Age of Aducanumab

, 2022
We review the implications of the recently approved aducanumab amyloid-β immunotherapy for treating Alzheimer disease with comorbid cerebral amyloid angiopathy.
Sveikata, Lukas, Viswanathan, Anand, Charidimou, Andreas, Andreas Charidimou, Anand Viswanathan, Lukas Sveikata   +5 more
core   +1 more source

Amyloid PET:A Questionable Single Primary Surrogate Efficacy Measure on Alzheimer Immunotherapy Trials [PDF]

, 2022
Using amyloid PET imaging as a single primary surrogate efficacy measure in Alzheimer's disease immunotherapy trials, as happened when the FDA granted accelerated approval of aducanumab, is unjustified.
Høilund-Carlsen, Poul F, Alavi, Abass, Revheim, Mona-Elisabeth, Satyamurthy, Nagichettiar, Barrio, Jorge R   +4 more
core   +1 more source